<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057005</url>
  </required_header>
  <id_info>
    <org_study_id>H12870</org_study_id>
    <secondary_id>ADVL</secondary_id>
    <nct_id>NCT00057005</nct_id>
    <nct_alias>NCT00601380</nct_alias>
  </id_info>
  <brief_title>Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation</brief_title>
  <acronym>ADVL</acronym>
  <official_title>Phase I Study of Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation (ADVL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants in this study have a hematologic malignancy which is a disorder in the bone&#xD;
      marrow that affects the body's ability to create blood. Participants might benefit from&#xD;
      receiving an allogeneic stem cell transplant (meaning the cells come from a donor). The&#xD;
      participants donor is a family member. Stem cells are cells in the bone marrow and blood that&#xD;
      can form a whole new blood system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are given high doses of chemotherapy before receiving a stem cell transplant to keep&#xD;
      their immune system from rejecting the donor stem cells and to kill any diseased cells that&#xD;
      remain in the body. To try and improve on the results of transplants that use high dose&#xD;
      chemotherapy alone, we are adding an agent called anti-CD45 to the treatment prior to the&#xD;
      stem cell transplant. Anti-CD45 is an antibody that specifically finds and destroys leukemia&#xD;
      cells.&#xD;
&#xD;
      Patients will receive the anti-CD45 with high dose chemotherapy (including Ara-C and&#xD;
      Cyclophosphamide) and radiotherapy. Patients will also receive Mesna which is a drug that&#xD;
      helps prevent bladder damage which can be caused by the cyclophosphamide. High dose&#xD;
      radiotherapy is also known as Total Body Irradiation or TBI.&#xD;
&#xD;
      Patients will receive the anti-CD45, high dose chemotherapy, and high dose radiotherapy&#xD;
      before the stem cell transplant. We expect participation in this study will last 2 years.&#xD;
&#xD;
      A summary of the treatment follows:&#xD;
&#xD;
        -  Day - 7: Ara-C, Cyclophosphamide, Mesna&#xD;
&#xD;
        -  Day - 6: Ara-C, Cyclophosphamide, Mesna&#xD;
&#xD;
        -  Day - 5: Ara-C, Anti-CD45&#xD;
&#xD;
        -  Day - 4: Anti-CD45, TBI&#xD;
&#xD;
        -  Day - 3: Anti-CD45, TBI&#xD;
&#xD;
        -  Day - 2: Anti-CD45, TBI&#xD;
&#xD;
        -  Day - 1: TBI&#xD;
&#xD;
        -  Day 0: Stem Cell Infusion (transplant)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the toxicity and the anti-tumor activity of anti-human CD45 antibodies (anti-CD45) administered to patients with relapsed/resistant leukemia prior to bone marrow transplantation.</measure>
    <time_frame>28 days and 100 days post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the effects of anti-CD45 on normal hematopoiesis and on complement levels and to describe the effects of anti-CD45 on leukemic blast cells.</measure>
    <time_frame>100 days post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>LEUKEMIA</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAMPATH-1H</intervention_name>
    <description>Day-8 through Day-6 according to institutional SOPs</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-CD45</intervention_name>
    <description>Day-5 400 Î¼g/kg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>day-7 through day-5 3000 mg/m2 q 12h</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Day-7 through Day-6 45 mg/kg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Days -7 and -6 45 mg/kg divided into 5 doses</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>150 cGy x 2 (5/6 matched related) 180 cGy x 2 (5/6 matched unrelated)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with advanced leukemia or other hematologic malignancy including AML, ALL,&#xD;
             CML, and MDS. Advanced features include: a) Induction failure, prolonged induction&#xD;
             beyond 6 weeks b) Incomplete response to salvage therapy c) CML in blast crisis or&#xD;
             acute leukemia in chemotherapy resistant relapse d) secondary leukemia or secondary&#xD;
             myelodysplastic disease&#xD;
&#xD;
          2. Patients must have a suitable HLA identical sibling donor or 5/6 matched related&#xD;
             donor, or fully matched or 5/6 matched unrelated donor, or haploidentical related&#xD;
             donor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients with a life expectancy (2X normal for age) 7. Patients with known allergy to&#xD;
        rat serum products 8. Patients with a Lansky score &lt;60% or Karnofsky score &lt;60%. 9.&#xD;
        Patients with severe infection that on evaluation by the PI precludes ablative&#xD;
        radio/chemotherapy or successful transplantation. 10. Patients with sever personality&#xD;
        disorder or mental illness. 11. Patients with documented HIV positivity 12. Pregnant or&#xD;
        lactating females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm K Brenner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 26, 2003</study_first_submitted>
  <study_first_submitted_qc>March 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2003</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Robert Krance</investigator_full_name>
    <investigator_title>Professor, Pediatrics-Hem-Onc Cell &amp; Gene</investigator_title>
  </responsible_party>
  <keyword>LEUKEMIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

